CD19 and precursor B-cell acute lymphoblastic leukemia: However, the ROC curve analysis revealed an even better clinical performance (AUC = 0.984) in discriminating B-ALL patients from CG (Figure 8E), compared to isolated EV-CD10+ (AUC = 0.860) and EV-CD19+ (AUC = 0,844) (Figure 7), highlighting the potential of these vesicles as biomarkers.